By Cecilia Butini
Merck KgaA stated Monday that it’s investing 40 million euros ($48.5 million) within the enlargement of its life science manufacturing capability within the U.S.
The German prescribed drugs and chemical substances firm stated the enlargement is about to extend capability and output at its Massachusetts and New Hampshire websites by the tip of 2021 and 2022, respectively. On account of the enlargement, almost 700 new manufacturing positions will probably be created, Merck stated.
The Massachusetts website, situated in Danvers, will result in the creation of about 400 jobs all through 2021 with an funding of about EUR21 million, based on Merck. The New Hampshire plant, situated in Jaffrey, will see a workforce enhance of 275 roles by 2022, with an funding of about EUR18.5 million.
The websites give attention to manufacture of merchandise for lifesaving therapies, together with Covid-19 vaccines, and on offering services for biopharmaceutical manufacturing, Merck stated. The enlargement plan for the 2 U.S. websites is a part of beforehand introduced investments within the life sciences enterprise totalling greater than EUR350 million.
Write to Cecilia Butini at [email protected]
(END) Dow Jones Newswires